Peripheral Androgen Blockade Feasible for PSA Relapse

Share this article:

Peripheral androgen blockade with a combination of finasteride and flutamide is feasible for prostate cancer patients who experience biochemical failure after definitive local therapy, researchers reported online ahead of print in Cancer.

In a study, 99 such patients received finasteride 5 mg orally per day and flutamide 250 mg orally three times a day. Investigators observed an 80% or greater decline in PSA in 96 patients (96%). Five-year overall survival was 87%. Toxicities were mild.

The researchers, led by J. Paul Monk, MD, of The Ohio State University School of Medicine in Columbus, noted that “because testosterone levels are not suppressed, this approach may be associated with less morbidity than conventional gonadal androgen suppression.”

Share this article:
You must be a registered member of RUN to post a comment.
close

Next Article in Prostate Cancer

More in Prostate Cancer

Blacks with Recurrent Prostate Cancer More Likely To Regret Treatment

Blacks with Recurrent Prostate Cancer More Likely To ...

Racial differences in prostate cancer (PCa) treatment regret more pronounced among those without sexual problems.

Androgen Deprivation Therapy (ADT) Raises Heart-Related Death Risk

Androgen Deprivation Therapy (ADT) Raises Heart-Related Death Risk

But overall risk of heart-related death risk from prostate cancer treatment is small, researchers say.

Men with More Female Partners Have Lower Prostate Cancer (PCa) Risk

Men with More Female Partners Have Lower Prostate ...

Men who have slept with more than 20 female partners are less likely to develop aggressive prostate cancer (PCa).